Evaluating the Efficacy and Safety of Inhaled SNS812 in Hospitalized Adults With Moderate to Severe COVID-19
A Single-Arm, Open-Label Pilot Study Evaluating the Efficacy and Safety of Inhaled SNS812 in Hospitalized Adults With Moderate to Severe COVID-19
This is an investigator-initiated, single-arm, open-label pilot study designed to explore the efficacy, safety, and tolerability of inhaled SNS812 in hospitalized adults with moderate-to-severe COVID-19.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years or older.
- Moderate-to-severe COVID-19.
- SARS-CoV-2 infection confirmed by an accepted NAAT, including RT-PCR, or an accepted antigen test using a respiratory specimen.
- Able to safely complete SNS812 administration under study-staff supervision.
- Participants of reproductive potential agree to use effective contraception as specified in the protocol.
- Written informed consent provided by the participant or legally authorized representative.
Exclusion Criteria:
- Known HIV infection, known HCV infection, or active HBV infection.
- Unable to cooperate with the SNS812 administration procedure.
- Participants who participate in other clinical trials and use other drugs in investigation before screening.
- Known hypersensitivity to SNS812 or its excipients.
- Pregnant or breastfeeding.
- Planned transfer to a non-study hospital within 24 hours such that primary assessments cannot be completed.
- Any medical condition, clinical circumstance, or other factor that, based on the participant's individual clinical condition and in the Investigator's judgment, may place the participant at increased risk, interfere with compliance with study procedures or completion of the study, or otherwise compromise the conduct of the study or interpretation of the study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SNS812 (MBS-COV)
Eligible participants will be assigned to multiple doses of the investigational drug. |
SNS812 is a potent siRNA treatment targeting mild to moderate COVID-19. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants achieving clinical improvement based on the WHO Clinical Progression Scale.
Time Frame: At Day 8
|
At Day 8
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SNS812CLIS01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.